SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Equashield Showcases Second Generation Closed System Transfer Device at Leading Pharmacy Events

First System to Prevent Syringe Plunger Contamination Demonstrated at Barcelona, New Orleans, and Montreal Conferences

BARCELONA, Spain, March 26, 2014 /PRNewswire/ --



Equashield (http://www.equashield.com), the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, today announced its participation in three upcoming pharmacy events.

The company will be demonstrating its new product, EQUASHIELD II, at the following conferences:


"We are receiving an influx of global interest in our second-generation solution, which was launched just a few months ago," said Marino Kriheli, Co-Founder of Equashield. "By covering more routes of exposure than other solutions, our product provides medical professionals with unprecedented safety. We are excited to demonstrate our solutions at these events and to meet with customers, distributors and partners."

Equashield representatives are available for meetings at EAHP, HOPA and ISOPP.

About  Equashield

Equashield is a provider of the world's safest Closed System Transfer Devices (CSTD), clinically proven to protect healthcare professionals from hazardous drug and vapor exposure. The company's flagship device, EQUASHIELD® II, is the fastest CSTD to deploy and easiest to use.  It is also the only truly closed device on the market, covering more routes of exposure than alternative systems and protecting against exposure to hazardous drug residue on contaminated syringe plungers. For more information, visit the company's website at http://www.equashield.com. Follow Equashield on Twitter: @equashield.

Media  Contact:
Finn Partners for Equashield
Ellie Hanson
[email protected]


SOURCE Equashield

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.